Menu
We back passionate founders and solutions that will change the future of medicine and personal wellness.
We invest with the mindset of reinvesting in follow on rounds to double down on our support.
We value long-term commitment, seeking to be involved throughout the growth cycle of all our investments.
We target industry blindspots.
Digital Health
Diagnostics
Artificial Intelligence and Machine Learning
Psychedelics
Hardware
Accessibility to treatment & resources
Thymia develops a gamified diagnostic tool that eliminates subjectivity from mental health assessments. Spearheaded by Dr. Emilia Molimpakis and Dr. Stefano Goria, they leverages ML algorithms to identify and track symptoms of depression, anxiety and other mental disorders, as well as their progression and severity throughout a patient’s treatment journey.
Guided by the founders’ unique mix of psychological expertise and ability to build incredibly complex systems, we believe Thymia will fundamentally alter how affective data is collected, analysed and leveraged to revolutionize mental health diagnosis and treatment.
Data must be the cornerstone of mental health innovations, and Thymia has found a way to objectify the subjective.
Lylu develops senior-friendly technologies that combine universal UI, personal support, and complete initialization that allows seniors to easily stay connected with their family and friends. Addressing a massively underserved market, Lylu is the portal through which seniors combat feelings of loneliness and isolation, all without creating a burden for their families.
Lylu stands to become the single touch point through which millions of seniors can drastically improve quality of life and their mental well-being. The elegant simplicity of their products allows seniors to not be left behind.
Too often society confuses growing old with growing stale, but Lylu wants to change how seniors engage with the internet and the world around them.
Wellspent bring consciousness back to social media apps, allowing users to make the most of their time and stay grounded in the moment. By developing a way to learn when a person transitions from actively enjoying to absent-mindedly consuming media, Wellspent seeks to interrupt maladaptive and harmful wastes of time.
Wellspent’s founding team is incredibly driven to shift users’ habits from instant gratification to long term wellbeing. Wellspent will be a key driver in reevaluating how individuals make the most of their time on their phone, as well as away from it.
WellSpent empowers users to consume media more consciously, preventing them from being consumed by it.
The UK’s first Contract Research Organization specifically focusing on psychedelic compounds, Clerkenwell Health facilitates first-class clinical trials for a rapidly growing and emerging class of pharmaceutical assets. Addressing the bottle neck between Novel Chemical Entities and their ability to be used in patients, Clerkenwell will set the global standard for how psychedelic compounds need to be trialled.
An exciting and innovative UK-based HealthTech company, currently operating in stealth mode, targets an industry blind spot that no one else has yet addressed. We are excited to share more details about this company soon.
Founders with decades of research experience in psychedelic therapy from University of Zurich, paired with extensive business and drug development experience combine at Reconnect Labs, who are developing new generation pharmaceutical drugs based on effective and proven plant medicine.
Reconnect’s team have synthesised a basket of compounds targeting multiple relevant indications, while firmly positioning the safety and tolerability for patients. They stand apart from their competitors by maximising both efficacy and practicality, all while being led by world-renowned experts in their fields.
The power of psychedelic medication to change lives is finally becoming apparent to the wider population, and Reconnect have been passionately devoted to placing the patient at the centre of this revolution.